Jefferies maintains a 'buy' rating on Diageo, forecasting a 35% rise in shares as the company executes a turnaround of its struggling US business, which accounts for 40% of sales. The plan focuses on stabilizing and regaining market share despite a weak US spirits market expected to shrink 3% this year. Key challenges include declining core brands and a weak presence in ready-to-drink products. Diageo's shares trade at a discount compared to peers, suggesting potential for re-rating as recovery progresses. Investors will watch the company's first-quarter trading update on November 5 for progress insights.
Diageo's turnaround plans are in focus as investors await updates on its US business recovery. For readers following Consumer Staples stocks, here is Pluang's market snapshot as of Sep 21, 2026 18:51 WIB: Among 43 priced US Consumer Staples stocks, 25 rose and 11 fell today. Notable movers include CELH (Celsius Holdings, Inc.) at USD 28.24 with a 1-day change of +0.79% and a typical hold time on Pluang of 66 days, SYY (SYSCO Corporation) at USD 79.63 with +0.73%, and DNUT (Krispy Kreme Inc) at USD 3.04 with +0.66%.
The Canadian Investment Regulatory Organization (CIRO) has temporarily halted trading of all shares of Bighorn Metals Corp. (symbol HRNY) as of 1:10 PM ET on October 19, 2026. The halt is pending further information from the company and aims to maint...
The HCA Healthcare Foundation awarded $25,000 to Waypoint (formerly Virginia Home for Boys and Girls) to expand its network of adults trained to support youth mental wellness across Virginia. This funding supports Waypoint's Therapeutic Resources tea...
Angle Advisors has appointed Chris Gessner as a Managing Director, bringing over 20 years of experience in corporate finance, including lending, private equity, and M&A advisory. Gessner's background spans various transaction types and industries suc...
The FDA has approved Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. This approval is based on the AZUR-1 trial showing 68% of patients achieved complete clinical response ...
Ethereum-based crypto Pepeto is in its final presale stages ahead of a Binance listing, with rapid investor interest driving record presale speed. Pepeto addresses issues Cardano aimed to fix, such as high fees and network congestion, offering zero-f...
